• NEBANNER

1-Bromo-2-methoxy-3-nitro-benzene

1-Bromo-2-methoxy-3-nitro-benzene

Short Description:

CAS no:98775-19-0

Chemical properties:Eltrombopag Intermediates


Product Detail

Product Tags

Uses

1-Bromo-2-methoxy-3-nitro-benzene is used as the intermediate of Eltrombopag .
Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also the first drug approved by the US FDA for the treatment of AA in recent 30 years.
In december2012, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC), so that hepatitis C patients with poor prognosis due to low platelet count can start and maintain interferon based standard therapy for liver diseases. On february3,2014, GlaxoSmithKline announced that the FDA granted the breakthrough treatment drug qualification of Eltrombopag for the treatment of hemopenia in patients with severe chemicalbook aplastic anemia (SAA) who did not fully respond to immunotherapy. On August 24, 2015, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in adults and children aged 1 year and over with chronic immune thrombocytopenia (ITP) who have insufficient response to corticosteroids, immunoglobulins or splenectomy. On january4,2018, Eltrombopag was approved to be listed in China for the treatment of primary immune thrombocytopenia (ITP).

Resource-integrated Product Line

wps_doc_0

Certificate

JIN DUN Medical has ISO qualification and meets GMP production standards, employed domestic and foreign drug synthesis experts with rich experience to guide company's R&D.

13
d68590fe
12
111

Advantages on Medical Customization

TECHNOL OGY ADVANTAGES
●High Pressure Catalytic Hydrogenation . High Pressure Hydrogenolysis Reaction . Cryogenic Reaction (<-78%C)
●Aromatic Heterocyclic Synthesis
●Rearrangement Reaction
●Chiral Resolution
●Heck, Suzuki,Negishi,Sonogashira . Gignard Reaction

JIN DUN R&D

Equipments

Our Lab has various experimental and testing equipments, such as: NMR (Bruker 400M)、HPLC、chiral-HPLC、LC-MS、LC-MS/MS (API 4000)、IR、UV、GC、GC-MS, Chromatography, Microwave Synthesizer, Parallel Synthesizer, Differential Scanning Calorimeter (DSC), Electron Microscope...

R&D Team

Jindun Medical has a group of professional R&D personnel, and employs many domestic and foreign drug synthesis experts to guide R&D, making our synthesis more accurate and efficient.

wps_doc_3

Case-Sharing

We have helped several top domestic pharmaceutical companies, such as Hansoh, Hengrui and HEC Pharm. Here we will show part of them.

wps_doc_4

Customzation Case One:

Cas No.: 110351-94-5

wps_doc_5

Customzation Case Two:

Cas No.: 144848-24-8

wps_doc_6

Customzation Case Three:

Cas No.: 200636-54-0

Cooperation Mode

1.Customize New Intermediates or APIs. Same as above case sharing, customers have the demands for specific Intermediates or APIs, and they can not find the needed products in the market,  then we can help to Customize.

2.Process Optimization for Old Products. Our team will help to Optimize and improve such production whose reaction route is old, production cost is high, and the efficiency is low. We can provide full documentation for technology transfer and process improvement, help customer for a more efficient production.

From drug targets to INDs, JIN DUN Medical provides you with one-stop personalized R&D solutions.

JIN DUN Medical insists on creating a team with dreams, making dignified products, meticulous, rigorous, and going all out to be a trusted partner and friend of customers!


  • Previous:
  • Next:

  • Write your message here and send it to us